A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma
2018-523-00US1
Phase 1 other active
Quick answer
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma for Lymphoma is a Phase 1 program (other) at Hutchmed Europe B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hutchmed Europe B.V.
- Indication
- Lymphoma
- Phase
- Phase 1
- Modality
- other
- Status
- active